VICP (Vicapsys Life Sciences) 1-Year Share Buyback Ratio : -0.90% (As of Sep. 2024 )

View and export this data going back to . Start your Free Trial

What is Vicapsys Life Sciences 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Vicapsys Life Sciences's current 1-Year Share Buyback Ratio was -0.90%.

VICP's 1-Year Share Buyback Ratio is ranked better than
80.45% of 1202 companies
in the Biotechnology industry
Industry Median: -13.65 vs VICP: -0.90

Competitive Comparison of Vicapsys Life Sciences's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, Vicapsys Life Sciences's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicapsys Life Sciences's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicapsys Life Sciences's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Vicapsys Life Sciences's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Vicapsys Life Sciences 1-Year Share Buyback Ratio Calculation

Vicapsys Life Sciences's 1-Year Share Buyback Ratio for the quarter that ended in Sep. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Sep. 2023 )	-	Shares Outstanding (EOP) (Sep. 2024 ))	/	Shares Outstanding (EOP) (Sep. 2023 )
	=	(32.071	-	32.371)	/	32.071
	=	-0.9%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicapsys Life Sciences (OTCPK:VICP) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Vicapsys Life Sciences 1-Year Share Buyback Ratio Related Terms

Vicapsys Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicapsys Life Sciences Inc (OTCPK:VICP) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

7778 Mcginnis Ferry Road, Suite 270, Suwanee, GA, USA, 30024

Website

https://www.vicapsys.com

Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

Executives

Moore Bobby M Jr	10 percent owner	4125 S.B. MERRION ROAD, LAKELAND FL 33810
Robert Grammen	10 percent owner	9180 GALLENA COURT, NAPLES FL 34109
Michael Yurkowski	director	1505 ELM STREET, #1504, DALLAS TX 75201
William P. Esping	10 percent owner	2828 ROUTH STREET, SUITE 500, DALLAS TX 75201
Rodger Rees	director	C/O BONDS.COM GROUP, INC., 1515 SOUTH FEDERAL HIGHWAY, SUITE 212, BOCA RATON FL 33432
Mark Feldmesser	director	641 UNIVERSITY BLVE, JUPITER FL 33458
Federico Pier	director	1004 PLUM DRIVE, IRVING TX 75063
Ryan Seddon	director, 10 percent owner	8120 BELVEDERE ROAD, SUITE 4, WEST PALM BEACH FL 33411

Vicapsys Life Sciences Headlines

From GuruFocus

ViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive Officer

By ACCESSWIRE ACCESSWIRE • 04-13-2022

Wildcat Capital Management, LLC's Strategic Acquisition in Vicapsys Life Sciences Inc

By GuruFocus News • 03-22-2025